{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:29:17Z","timestamp":1772119757445,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11010-023-04706-2","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T02:15:52Z","timestamp":1680488152000},"page":"2907-2916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cisplatin treatment reduces contraction to angiotensin II by altering expression of angiotensin II receptors: a pilot study"],"prefix":"10.1007","volume":"478","author":[{"given":"Kristen Renee","family":"McSweeney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Kate","family":"Gadanec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kubatka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Caprnda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovit","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Prosecky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delian","family":"Delev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kruzliak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasso","family":"Apostolopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Zulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,1]]},"reference":[{"key":"4706_CR1","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31:1869\u20131883","journal-title":"Oncogene"},{"key":"4706_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12012-021-09636-3","volume":"21","author":"YA Khadrawy","year":"2021","unstructured":"Khadrawy YA, Hosny EN, El-Gizawy MM, Sawie HG, Aboul Ezz HS (2021) The effect of curcumin nanoparticles on cisplatin-induced cardiotoxicity in male Wistar albino rats. Cardiovasc Toxicol 21:433\u2013443","journal-title":"Cardiovasc Toxicol"},{"key":"4706_CR3","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.3390\/cancers13071572","volume":"13","author":"KR McSweeney","year":"2021","unstructured":"McSweeney KR, Gadanec LK, Qaradakhi T, Ali BA, Zulli A, Apostolopoulos V (2021) Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers 13:1572","journal-title":"Cancers"},{"key":"4706_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1172\/JCI200215606","volume":"110","author":"G Ramesh","year":"2002","unstructured":"Ramesh G, Reeves WB (2002) TNF-\u03b1 mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Investig 110:835\u2013842","journal-title":"J Clin Investig"},{"key":"4706_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/sj.ki.5002242","volume":"72","author":"B Zhang","year":"2007","unstructured":"Zhang B, Ramesh G, Norbury C, Reeves W (2007) Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-\u03b1 produced by renal parenchymal cells. Kidney Int 72:37\u201344","journal-title":"Kidney Int"},{"key":"4706_CR6","doi-asserted-by":"publisher","first-page":"109693","DOI":"10.1016\/j.biopha.2019.109693","volume":"122","author":"P Liu","year":"2020","unstructured":"Liu P, Li X, Lv W, Xu Z (2020) Inhibition of CXCL1-CXCR2 axis ameliorates cisplatin-induced acute kidney injury by mediating inflammatory response. Biomed Pharmacother 122:109693","journal-title":"Biomed Pharmacother"},{"key":"4706_CR7","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.bbagen.2013.12.007","volume":"1840","author":"A Kodama","year":"2014","unstructured":"Kodama A, Watanabe H, Tanaka R, Kondo M, Chuang VTG, Wu Q, Endo M, Ishima Y, Fukagawa M, Otagiri M (2014) Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity. Biochim Biophys Acta 1840:1152\u20131162","journal-title":"Biochim Biophys Acta"},{"key":"4706_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","volume":"17","author":"M Paz Ocaranza","year":"2020","unstructured":"Paz Ocaranza M, Riquelme JA, Garc\u00eda L, Jalil JE, Chiong M, Santos RA, Lavandero S (2020) Counter-regulatory renin\u2013angiotensin system in cardiovascular disease. Nat Rev Cardiol 17:116\u2013129","journal-title":"Nat Rev Cardiol"},{"key":"4706_CR9","first-page":"615","volume":"6","author":"RS Padda","year":"2015","unstructured":"Padda RS, Shi Y, Lo C-S, Zhang S-L, Chan JS (2015) Angiotensin-(1\u20137): a novel peptide to treat hypertension and nephropathy in diabetes? J Diabetes Metab 6:615","journal-title":"J Diabetes Metab"},{"key":"4706_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/039463201402700110","volume":"27","author":"A Zulli","year":"2014","unstructured":"Zulli A, Hare DL, Buxton BF, Widdop RE (2014) Vasoactive role for angiotensin II type 2 receptors in human radial artery. Int J Immunopathol Pharmacol 27:79\u201385","journal-title":"Int J Immunopathol Pharmacol"},{"key":"4706_CR11","doi-asserted-by":"publisher","first-page":"F698","DOI":"10.1152\/ajprenal.90308.2008","volume":"295","author":"AA Banday","year":"2008","unstructured":"Banday AA, Lokhandwala MF (2008) Oxidative stress-induced renal angiotensin AT1 receptor upregulation causes increased stimulation of sodium transporters and hypertension. Am J Physiol-Renal Physiol 295:F698\u2013F706","journal-title":"Am J Physiol-Renal Physiol"},{"key":"4706_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11906-018-0900-0","volume":"20","author":"R Satou","year":"2018","unstructured":"Satou R, Penrose H, Navar LG (2018) Inflammation as a regulator of the renin-angiotensin system and blood pressure. Curr Hypertens Rep 20:1\u20139","journal-title":"Curr Hypertens Rep"},{"key":"4706_CR13","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1002\/cphy.c120002","volume":"2","author":"MC Chappell","year":"2012","unstructured":"Chappell MC (2012) The non-classical renin-angiotensin system and renal function. Compr Physiol 2:2733","journal-title":"Compr Physiol"},{"key":"4706_CR14","first-page":"1","volume-title":"Angiotensin-(1\u20137): a comprehensive review","author":"MC Chappell","year":"2019","unstructured":"Chappell MC (2019) The angiotensin-(1\u20137) axis: formation and metabolism pathways. In: Santos RAS (ed) Angiotensin-(1\u20137): a comprehensive review. Springer, Cham, pp 1\u201326"},{"key":"4706_CR15","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-12-0341","volume":"216","author":"RA Santos","year":"2013","unstructured":"Santos RA, Ferreira AJ, Verano-Braga T, Bader M (2013) Angiotensin-converting enzyme 2, angiotensin-(1\u20137) and Mas: new players of the renin\u2013angiotensin system. J Endocrinol 216:R1\u2013R17","journal-title":"J Endocrinol"},{"key":"4706_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MNH.0000000000000373","volume":"27","author":"MC Van Haaster","year":"2018","unstructured":"Van Haaster MC, McDonough AA, Gurley SB (2018) Blood pressure regulation by the angiotensin type 1 receptor in the proximal tubule. Curr Opin Nephrol Hypertens 27:1","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4706_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1161\/01.RES.0000166326.91395.74","volume":"96","author":"V Esteban","year":"2005","unstructured":"Esteban V, Ruperez M, S\u00e1nchez-L\u00f3pez E, Rodr\u00edguez-Vita J, Lorenzo O, Demaegdt H, Vanderheyden P, Egido J, Ruiz-Ortega M (2005) Angiotensin IV activates the nuclear transcription factor-\u03baB and related proinflammatory genes in vascular smooth muscle cells. Circ Res 96:965\u2013973","journal-title":"Circ Res"},{"key":"4706_CR18","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1093\/ajh\/hpv054","volume":"28","author":"J Wysocki","year":"2015","unstructured":"Wysocki J, Ye M, Batlle D (2015) Plasma and kidney angiotensin peptides: importance of the aminopeptidase A\/angiotensin III axis. Am J Hypertens 28:1418\u20131426","journal-title":"Am J Hypertens"},{"key":"4706_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1042\/CS20130396","volume":"127","author":"J Gao","year":"2014","unstructured":"Gao J, Marc Y, Iturrioz X, Leroux V, Balavoine F, Llorens-Cortes C (2014) A new strategy for treating hypertension by blocking the activity of the brain renin\u2013angiotensin system with aminopeptidase A inhibitors. Clin Sci 127:135\u2013148","journal-title":"Clin Sci"},{"key":"4706_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejphar.2012.04.027","volume":"685","author":"S Okui","year":"2012","unstructured":"Okui S, Yamamoto H, Li W, Gamachi N, Fujita Y, Kashiwamura S-i, Miura D, Takai S, Miyazaki M, Urade M (2012) Cisplatin-induced acute renal failure in mice is mediated by chymase-activated angiotensin-aldosterone system and interleukin-18. Eur J Pharmacol 685:149\u2013155","journal-title":"Eur J Pharmacol"},{"key":"4706_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/bcpt.12538","volume":"118","author":"MA Morsy","year":"2016","unstructured":"Morsy MA, Heeba GH (2016) Nebivolol ameliorates cisplatin-induced nephrotoxicity in rats. Basic Clin Pharmacol Toxicol 118:449\u2013455","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4706_CR22","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1158\/1535-7163.MCT-10-0535","volume":"9","author":"N Tanaka","year":"2010","unstructured":"Tanaka N, Miyajima A, Kosaka T, Shirotake S, Hasegawa M, Kikuchi E, Oya M (2010) Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer CDDP upregulates AT1R and enhances VEGF production. Mol Cancer Ther 9:2982\u20132992","journal-title":"Mol Cancer Ther"},{"key":"4706_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3389\/fmolb.2020.00096","volume":"7","author":"GR Estrela","year":"2020","unstructured":"Estrela GR, Wasinski F, Gregnani MF, Freitas-Lima LC, Arruda AC, Morais RL, Malheiros DM, Camara NO, Pesquero JB, Bader M (2020) Angiotensin-converting enzyme inhibitor protects against cisplatin nephrotoxicity by modulating kinin B1 receptor expression and aminopeptidase P activity in mice. Front Mol Biosci 7:96","journal-title":"Front Mol Biosci"},{"key":"4706_CR24","doi-asserted-by":"publisher","first-page":"273784","DOI":"10.1155\/2015\/273784","volume":"2015","author":"N Enatsu","year":"2015","unstructured":"Enatsu N, Miyake H, Chiba K, Fujisawa M (2015) Candesartan mediated amelioration of cisplatin-induced testicular damage is associated with alterations in expression patterns of nephrin and podocin. Biomed Res Int 2015:273784","journal-title":"Biomed Res Int"},{"key":"4706_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejphar.2014.12.008","volume":"748","author":"S Malik","year":"2015","unstructured":"Malik S, Suchal K, Gamad N, Dinda AK, Arya DS, Bhatia J (2015) Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis. Eur J Pharmacol 748:54\u201360","journal-title":"Eur J Pharmacol"},{"key":"4706_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1248\/bpb.b20-00174","volume":"43","author":"A Hosoda","year":"2020","unstructured":"Hosoda A, Matsumoto Y, Toriyama Y, Tsuji T, Yoshida Y, Masamichi S, Kohno T (2020) Telmisartan exacerbates cisplatin-induced nephrotoxicity in a mouse model. Biol Pharm Bull 43:1331\u20131337","journal-title":"Biol Pharm Bull"},{"key":"4706_CR27","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.34172\/npj.2022.10","volume":"11","author":"S Kasaei","year":"2021","unstructured":"Kasaei S, Pezeshki Z, Karimi F, Lak Z, Choopani S, Talebi A, Nematbakhsh M (2021) Angiotensin 1\u20137 and losartan worsen the cisplatin induced nephrotoxicity in female rats. J Nephropharmacol 11:e10","journal-title":"J Nephropharmacol"},{"key":"4706_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fphar.2017.00196","volume":"8","author":"E Herrad\u00f3n","year":"2017","unstructured":"Herrad\u00f3n E, Gonz\u00e1lez C, Uranga JA, Abalo R, Mart\u00edn MI, L\u00f3pez-Miranda V (2017) Characterization of cardiovascular alterations induced by different chronic cisplatin treatments. Front Pharmacol 8:196","journal-title":"Front Pharmacol"},{"key":"4706_CR29","first-page":"247","volume":"23","author":"J Nuver","year":"2010","unstructured":"Nuver J, De Haas EC, Van Zweeden M, Gietema JA, Meijer C (2010) Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 23:247\u2013253","journal-title":"Oncol Rep"},{"key":"4706_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/eurheartj\/ehac544.3046","volume":"43","author":"H Pan","year":"2022","unstructured":"Pan H, Song X, Rajewski A, Wickline S (2022) Single cell sequencing unveils endothelial alterations after cisplatin treatment. Eur Heart J 43:544","journal-title":"Eur Heart J"},{"key":"4706_CR31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3892\/br.2014.349","volume":"2","author":"Y Jiang","year":"2014","unstructured":"Jiang Y, Shan S, Gan T, Zhang X, Lu X, Hu H, Wu Y, Sheng J, Yang J (2014) Effects of cisplatin on the contractile function of thoracic aorta of Sprague\u2013Dawley rats. Biomed Rep 2:893\u2013897","journal-title":"Biomed Rep"},{"key":"4706_CR32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s00223-019-00600-6","volume":"105","author":"T Qaradakhi","year":"2019","unstructured":"Qaradakhi T, Gadanec LK, Tacey AB, Hare DL, Buxton BF, Apostolopoulos V, Levinger I, Zulli A (2019) The effect of recombinant undercarboxylated osteocalcin on endothelial dysfunction. Calcif Tissue Int 105:546\u2013556","journal-title":"Calcif Tissue Int"},{"key":"4706_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4103\/2277-9175.178797","volume":"5","author":"A Dehghani","year":"2016","unstructured":"Dehghani A, Saberi S, Nematbakhsh M (2016) Cisplatin-induced nephrotoxicity alters blood pressure response to angiotensin II administration in rats. Adv Biomed Res 5:53","journal-title":"Adv Biomed Res"},{"key":"4706_CR34","doi-asserted-by":"publisher","first-page":"e9628","DOI":"10.15252\/msb.20209628","volume":"16","author":"S Sinha","year":"2020","unstructured":"Sinha S, Cheng K, Sch\u00e4ffer AA, Aldape K, Schiff E, Ruppin E (2020) In vitro and in vivo identification of clinically approved drugs that modify ACE 2 expression. Mol Syst Biol 16:e9628","journal-title":"Mol Syst Biol"},{"key":"4706_CR35","doi-asserted-by":"publisher","first-page":"19087","DOI":"10.1073\/pnas.0602715103","volume":"103","author":"R Ramchandran","year":"2006","unstructured":"Ramchandran R, Takezako T, Saad Y, Stull L, Fink B, Yamada H, Dikalov S, Harrison DG, Moravec C, Karnik SS (2006) Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin response. Proc Natl Acad Sci 103:19087\u201319092","journal-title":"Proc Natl Acad Sci"},{"key":"4706_CR36","first-page":"F1025","volume-title":"Targeting AT2 receptors in renal disease","author":"T Yang","year":"2021","unstructured":"Yang T (2021) Targeting AT2 receptors in renal disease. American Physiological Society, Rockville, pp F1025\u2013F1027"},{"key":"4706_CR37","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/ijms23020927","volume":"23","author":"G Civieri","year":"2022","unstructured":"Civieri G, Iop L, Tona F (2022) Antibodies against angiotensin II type 1 and endothelin 1 type A receptors in cardiovascular pathologies. Int J Mol Sci 23:927","journal-title":"Int J Mol Sci"},{"key":"4706_CR38","doi-asserted-by":"publisher","first-page":"e68036","DOI":"10.1371\/journal.pone.0068036","volume":"8","author":"RR Singh","year":"2013","unstructured":"Singh RR, Lankadeva YR, Denton KM, Moritz KM (2013) Improvement in renal hemodynamics following combined angiotensin II infusion and AT1R blockade in aged female sheep following fetal unilateral nephrectomy. PLoS ONE 8:e68036","journal-title":"PLoS ONE"},{"key":"4706_CR39","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1681\/ASN.2015060683","volume":"27","author":"J Zhang","year":"2016","unstructured":"Zhang J, Rudemiller NP, Patel MB, Wei Q, Karlovich NS, Jeffs AD, Wu M, Sparks MA, Privratsky JR, Herrera M (2016) Competing actions of type 1 angiotensin II receptors expressed on T lymphocytes and kidney epithelium during cisplatin-induced AKI. J Am Soc Nephrol 27:2257","journal-title":"J Am Soc Nephrol"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-023-04706-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-023-04706-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-023-04706-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T03:11:51Z","timestamp":1699240311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-023-04706-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["4706"],"URL":"https:\/\/doi.org\/10.1007\/s11010-023-04706-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2343094\/v1","asserted-by":"object"}]},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,1]]},"assertion":[{"value":"4 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest. Dr Zulli is part owner of Zultek Engineering.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}